Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans

GlobeNewswire January 4, 2017

Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH

GlobeNewswire January 3, 2017

Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins

GlobeNewswire December 5, 2016

Akari Therapeutics to Attend Upcoming Investor Conferences In November

GlobeNewswire November 11, 2016

Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology

GlobeNewswire November 3, 2016

Akari Therapeutics Appoints New Members to its Board of Directors

GlobeNewswire October 14, 2016

Akari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York City

GlobeNewswire September 16, 2016

A Peek Into The Markets: Dow Futures Tumble Over 100 Points

Benzinga.com  September 12, 2016

Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria

GlobeNewswire September 12, 2016

Akari Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference

GlobeNewswire August 4, 2016

Akari Therapeutics Gets Regulatory Approval To Conduct Phase 2 Study In Paroxysmal Nocturnal Hemoglobinuria

Benzinga.com  July 13, 2016

Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria

GlobeNewswire July 13, 2016

Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria

GlobeNewswire July 12, 2016

Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin

GlobeNewswire July 6, 2016

Akari Therapeutics to Present at the JMP 2016 Life Sciences Conference

GlobeNewswire June 15, 2016

Akari Therapeutics to Present at the Jefferies 2016 Healthcare Conference

GlobeNewswire May 26, 2016

Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome

GlobeNewswire May 23, 2016

Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated

GlobeNewswire May 19, 2016

Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome

GlobeNewswire May 12, 2016

Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology

GlobeNewswire April 14, 2016